The present disclosure relates to antibodies includinghuman antibodies and antigen- binding portions thereof thatspecifically bind to MAdCAM, preferably human MAdCAM and thatfunction to inhibit MAdCAM. The disclosure also relates to humananti-MAdCAM antibodies and antigen-binding portions thereof. Thedisclosure also relates to antibodies that are chimeric, bispecific,derivatized, single chain antibodies or portions of fusion proteins. Thedisclosure also relates to isolated heavy and light chainimmunoglobulins derived from human anti-MAdCAM antibodies and nucleicacid molecules encoding such immunoglobulins. The presentdisclosure also relates to methods of making human anti- MAdCAMantibodies, compositions comprising these antibodies and methods ofusing the antibodies and compositions for diagnosis and treatment.The disclosure also provides gene therapy methods using nucleicacid molecules encoding the heavy and/or light immunoglobulinmolecules that comprise the human anti-MAdCAM antibodies. Thedisclosure also relates to transgenic animals or plants comprisingnuclpeic acid molecules of the disclosure.
